Incremental Value of 18F-PSMA-1007 PET/CT in Detection of Metastatic Renal Cell Carcinoma to the Brain.

Authors :: Sadeq A
Usmani S
Esmail AA
Fathallah W
Alfeeli MA
Marafi F
Source :: Clinical nuclear medicine [Clin Nucl Med] 2022 Jul 01; Vol. 47 (7), pp. 627-628. Date of Electronic Publication: 2022 Apr 27.
Publication Year :: 2022
Abstract: Abstract: 18F-PSMA PET/CT is an emerging standard of care in staging prostate cancer, evaluating biochemical recurrence and response to therapy. Despite the nomenclature, PSMA expression is also documented at the tumor-associated neovasculature of other malignant solid tumors including renal cell carcinoma. We report a case of 44-year-old man known to have renal cell carcinoma who underwent 18F-PSMA and 18F-FDG PET/CT for restaging after radical nephrectomy. A well-defined solitary cerebellar lesion with marked PSMA expression and equivocal FDG uptake was noted. MRI brain confirmed a matching cerebellar metastatic lesion. 18F-PSMA expression in the metastatic RCC raises a prospective guide to futuristic theragnostic uses.<br />Competing Interests: Conflicts of interest and sources of funding: none declared.<br /> (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)

Subjects :: Adult
Brain diagnostic imaging
Brain pathology
Gallium Radioisotopes
Humans
Male
Niacinamide analogs & derivatives
Oligopeptides
Positron Emission Tomography Computed Tomography
Prospective Studies
Radiopharmaceuticals
Carcinoma, Renal Cell diagnostic imaging
Carcinoma, Renal Cell pathology
Kidney Neoplasms diagnostic imaging
Kidney Neoplasms pathology
Prostatic Neoplasms pathology

Full Text Access

Tools